Blue Earth Therapeutics has secured an "innovation passport" from the U.K.'s Innovative Licensing and Access Pathway (ILAP) for its investigational therapeutic radiopharmaceutical lutetium-177 (Lu-177) rhPSMA-10.1 for treatment of metastatic prostate cancer.
The passport is the entry point to ILAP's process of accelerating time to market for investigational devices. ILAP coordinates a company's interaction with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and the process of submitting marketing authorization applications, Blue Earth said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
